S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Price, News & Analysis

$3.64
-0.22 (-5.71%)
(As of 03/27/2024 ET)
Today's Range
$3.53
$3.88
50-Day Range
$3.28
$4.24
52-Week Range
$1.30
$4.45
Volume
1.49 million shs
Average Volume
1.14 million shs
Market Capitalization
$44.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
312.7% Upside
$15.00 Price Target
Short Interest
Healthy
16.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Cellectar Biosciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.02) to ($2.23) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.16 out of 5 stars

Medical Sector

571st out of 939 stocks

Pharmaceutical Preparations Industry

264th out of 422 stocks

CLRB stock logo

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

CLRB Stock News Headlines

Q4 2023 Cellectar Biosciences Inc Earnings Call
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Earnings Preview For Cellectar Biosciences
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Cellectar Biosciences Inc
Cellectar Biosciences Inc (CLRB)
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CLRB
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+312.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-28,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.51 per share

Miscellaneous

Free Float
11,723,000
Market Cap
$44.67 million
Optionable
Optionable
Beta
0.93
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

CLRB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings
or view top-rated stocks.

What is Cellectar Biosciences' stock price target for 2024?

1 brokerages have issued twelve-month price targets for Cellectar Biosciences' shares. Their CLRB share price targets range from $10.00 to $20.00. On average, they expect the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 312.7% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2024?

Cellectar Biosciences' stock was trading at $2.77 at the beginning of 2024. Since then, CLRB stock has increased by 31.2% and is now trading at $3.6350.
View the best growth stocks for 2024 here
.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decrease in short interest in March. As of March 15th, there was short interest totaling 1,880,000 shares, a decrease of 6.5% from the February 29th total of 2,010,000 shares. Based on an average trading volume of 1,760,000 shares, the days-to-cover ratio is currently 1.1 days. Approximately 16.9% of the company's shares are short sold.
View Cellectar Biosciences' Short Interest
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (15.58%), ADAR1 Capital Management LLC (11.21%), Nantahala Capital Management LLC (10.99%), Worth Venture Partners LLC (5.65%), Vanguard Group Inc. (3.93%) and Vanguard Group Inc. (3.93%).
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners